Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIT2: ianalumab plus eltrombopag versus placebo plus eltrombopag in primary immune thrombocytopenia
2022-001627-32Phase 3Active
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in immune thrombocytopenia (ITP) (3 arms), sponsored by Novartis. Primary endpoint: Time to treatment failure. Started Oct 2022; status: active.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2022-001627-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001627-32.